You just read:

Janssen Announces ERLEADA® (apalutamide) Phase 3 TITAN Study Unblinded as Dual Primary Endpoints Achieved in Clinical Program Evaluating Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Jan 30, 2019, 08:00 ET